{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-052170","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-08-04T11:49:13+00:00","discovered_at":"2026-08-04T11:50:00.291040+00:00","generated_at":"2026-08-04T11:50:10.367528+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO","bullets":["Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).","Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval in March 2026.","RM-718 Phase 2: -11.6% mean BMI reduction at 16 weeks (n=7) in acquired HO, comparable to setmelanotide.","Net loss $(50.4)M ($(0.73)/share) vs $(48.0)M ($(0.75)/share) in Q2 2025.","Cash $330.9M; FY 2026 Non-GAAP OpEx guidance $363M-$397M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-052170","json":"https://secwatch.observer/filing/0001628280-26-052170.json","markdown":"https://secwatch.observer/filing/0001628280-26-052170.md","text":"https://secwatch.observer/filing/0001628280-26-052170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/0001628280-26-052170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026052170/rytm-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:50:10.367528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}